Last Updated: 19 Sep 2024
Executive Summary
Pacira BioSciences, Inc. (PCRX) is a leading provider of non-opioid pain management and regenerative health solutions. With a market capitalization of $675.76 million, the company has shown strong financial performance with an EBITDA of $175.34 million and an EPS of $1.34. However, recent quarterly earnings growth has been negative (-0.245%), and the stock price has declined to $14.69, below its 50-day and 200-day moving averages.
Company Overview
Pacira BioSciences is headquartered in Parsippany, New Jersey, and provides a range of pain management products, including EXPAREL and iovera°. The company's focus on non-opioid solutions aligns with the growing demand for alternative pain management options.
Fundamental Analysis
PCRX has a trailing PE ratio of 10.93 and a forward PE ratio of 3.697. The company's profit margin is 9.21%, and its operating margin is 17.4%. Pacira BioSciences has a strong balance sheet with a book value of $19.07 per share and no outstanding debt.
Technical Analysis
The stock price of PCRX has been trending down in recent months, breaking below its key moving averages. The 52-week high was $35.95, while the 52-week low was $11.16. The relative strength index (RSI) is currently at 35.5, indicating oversold conditions.
Short Term Outlook
In the short term, PCRX may continue to face headwinds due to negative earnings growth and technical weakness. The stock price could test the $11.16 support level.
Long Term Outlook
The long-term outlook for PCRX is more positive. The company's focus on non-opioid pain management positions it well for growth in a rapidly expanding market. Additionally, the company has a strong pipeline of new products in development.
Analyst Recommendations
Analysts are divided on PCRX, with 2 strong buy ratings, 2 buy ratings, 4 hold ratings, and 2 sell ratings. The average analyst target price is $23.75, implying a potential upside of 61.4%.
